-

Bayer Selects Interpublic as Global Media, Production and Creative Agency Partner for Consumer Health Division

BASEL, Switzerland--(BUSINESS WIRE)--The Consumer Health division of Bayer has selected Interpublic Group (NYSE: IPG) as the global agency partner for all creative, production and media, responsible for marketing activities for some of the most trusted and well-known brands in self-care.

The selection of an integrated agency across brands and regions represents a new era in how Bayer intends to grow consumer love and trust in iconic brands like Aspirin, Bepanthen, Claritin, Canesten and more. The shift intends to capitalize on the acceleration of GenAI tools and capabilities to better engage with consumers at the local level.

“Our new agency model addresses two competing forces in today's marketing landscape - the need for more connection and individuality alongside greater efficiency and automation," said David Evendon-Challis from the Consumer Health Division of Bayer. “IPG understands how data, AI and creative must converge in this new era and came forward with a strong offering that brings together world class capabilities, innovative technologies, and creativity. We are excited for them to join with us on this journey and by the opportunity of what is possible when their planned combination with Omnicom is complete.”

“We are honored and energized by Bayer’s decision,” said Philippe Krakowsky, Chief Executive Officer, Interpublic Group. “In today’s fragmented and fast-moving marketing environment, clients are looking for partners who can integrate creativity and media with data and technology in ways that are seamless and connected. What makes this opportunity exciting is the scale and ambition of Bayer’s portfolio — trusted brands with enormous reach and impact. By bringing the full IPG ecosystem together, we will deliver bold ideas, smarter media, and technology-enabled production that accelerate growth, deepen consumer trust, and drive results across markets. We look forward to tapping additional talent and capabilities on Bayer’s behalf once we join forces with Omnicom.”

The new integrated agency approach is designed to deliver world-class media buying power across the world to enhance Bayer’s ability to connect with consumers with content that is more personalized and responsive to their needs. It is also built on a flexible operating model to scale brand building activities with global consistency while maintaining local relevance.

After a transition and handover period, Bayer expects to go live with the new agency structure on January 1.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to www.bayer.com.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Contacts

Contact for media inquiries:
Ex-U.S.
Jeff Donald
Jeffrey.donald@bayer.com

U.S.
Christin Miller
usmediainqueries@bayer.com

Find more information at www.bayer.com.

Bayer

GER:BAYN

Release Versions

Contacts

Contact for media inquiries:
Ex-U.S.
Jeff Donald
Jeffrey.donald@bayer.com

U.S.
Christin Miller
usmediainqueries@bayer.com

Find more information at www.bayer.com.

More News From Bayer

Bayer and Vanderbilt University Medical Center to Advance Treatments for Cardiovascular and Kidney Diseases

BERLIN & NASHVILLE, Tenn.--(BUSINESS WIRE)--Bayer and Vanderbilt University Medical Center (VUMC) today announced that they have entered a strategic five-year collaboration agreement to advance innovative therapies from target identification through Investigational New Drug (IND) application. The agreement spans across all indications currently pursued by Bayer, initially focusing on cardiovascular and kidney diseases, two therapeutic areas with significant unmet medical need. The collaboration...

Bayer welcomes the U.S. Supreme Court decision to review the Durnell case in the Roundup™ litigation

LEVERKUSEN--(BUSINESS WIRE)--The U.S. Supreme Court today announced that it will review the Durnell Roundup™ case. Monsanto petitioned the court to hear Durnell in April 2025 and address the split in authority among federal circuit courts on the application of federal preemption, a cross-cutting issue in the Roundup™ litigation. The company expects a decision on the merits during the Court’s 2026 session, which ends in June. “The Supreme Court decision to take the case is good news for U.S. far...

Bayer Accelerates Pharma Growth on High-Value Portfolio

SAN FRANCISCO--(BUSINESS WIRE)--On the occasion of the 44th J.P. Morgan Healthcare Conference in San Francisco, Bayer AG today unveiled the strategic focus for its Pharmaceuticals Division in 2026. Capitalizing on new launch momentum, the company will drive significant global regulatory expansions and market penetration across its pharmaceutical portfolio. High-value commercial products and an accelerating modality-rich pipeline across oncology, cardiology, neurology, and immunology have firmly...
Back to Newsroom